Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -19.76% is 821% below its 5-year average of 2.74%, near the high end of its 5-year range (-227.03%–40.21%).
72.05% above its 12-month average of -70.69%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -227.03%.
NET PROFIT MARGIN
-19.76%
NET PROFIT MARGIN AVG TTM
-70.69%
NET PROFIT MARGIN AVG 3Y
1.03%
NET PROFIT MARGIN AVG 5Y
2.74%
NET PROFIT MARGIN AVG 10Y
-0.65%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+72.05%
CURRENT VS 3Y AVG
-2016.66%
CURRENT VS 5Y AVG
-820.62%
CURRENT VS 10Y AVG
-2951.59%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 729 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Organogenesis Holdings Inc.
Market Cap
$169.85M
Net Profit Margin
-19.76%
TTM Avg
-70.69%
3Y Avg
1.03%
5Y Avg
2.74%
Market Cap
$171.62M
Net Profit Margin
-170.10%
TTM Avg
-145.13%
3Y Avg
-100.04%
5Y Avg
-83.24%
Market Cap
$173.23M
Net Profit Margin
-229.20%
TTM Avg
-206.03%
3Y Avg
-659.07%
5Y Avg
-1951.89%
Market Cap
$166.35M
Net Profit Margin
4.66%
TTM Avg
-8.57%
3Y Avg
-15.00%
5Y Avg
-10.75%
Market Cap
$173.79M
Net Profit Margin
-435.83%
TTM Avg
-267.41%
3Y Avg
-1429.19%
5Y Avg
-1238.68%
Market Cap
$173.98M
Net Profit Margin
-117.04%
TTM Avg
-61.51%
3Y Avg
-173.42%
5Y Avg
-194.84%
Market Cap
$164.16M
Net Profit Margin
-80.29%
TTM Avg
-52.87%
3Y Avg
-55.88%
5Y Avg
-51.71%
Market Cap
$176.36M
Net Profit Margin
0.00%
TTM Avg
-2904.41%
3Y Avg
-1452.20%
5Y Avg
-968.14%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Organogenesis Holdings Inc. (ORGO) | $169.85M | -19.76% | -70.69% | 1.03% | 2.74% |
| MediWound Ltd. (MDWD)vs › | $171.62M | -170.10% | -145.13% | -100.04% | -83.24% |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.23M | -229.20% | -206.03% | -659.07% | -1951.89% |
| OptimizeRx Corp. (OPRX)vs › | $166.35M | 4.66% | -8.57% | -15.00% | -10.75% |
| Nkarta, Inc. (NKTX)vs › | $173.38M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cue Biopharma, Inc. (CUE)vs › | $173.79M | -435.83% | -267.41% | -1429.19% | -1238.68% |
| Precision BioSciences, Inc. (DTIL)vs › | $173.98M | -117.04% | -61.51% | -173.42% | -194.84% |
| Quanterix Corporation (QTRX)vs › | $164.16M | -80.29% | -52.87% | -55.88% | -51.71% |
| Compass Therapeutics, Inc. (CMPX)vs › | $176.36M | 0.00% | -2904.41% | -1452.20% | -968.14% |
| Coherus Oncology, Inc. (CHRS)vs › | $163.00M | -257.10% | -196.56% | -155.96% | -114.00% |
Operating Margin
9.9%
Net Profit Margin
-19.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -227.03% |
| 2026-03-31 | -150.85% |
| 2025-12-31 | 19.42% |
| 2025-09-30 | 14.33% |
| 2025-06-30 | -9.32% |
| 2025-03-31 | -21.74% |
| 2024-12-31 | 6.06% |
| 2024-09-30 | 10.71% |
| 2024-06-30 | -13.09% |
| 2024-03-31 | -1.91% |
| 2023-12-31 | -0.57% |
| 2023-09-30 | 2.92% |
| 2023-06-30 | 4.53% |
| 2023-03-31 | -2.76% |
| 2022-12-31 | 6.48% |
| 2022-09-30 | 0.18% |
| 2022-06-30 | 7.20% |
| 2022-03-31 | -0.94% |
| 2021-12-31 | 40.21% |
| 2021-09-30 | 11.06% |
| 2021-06-30 | 16.79% |
| 2021-03-31 | 9.70% |
| 2020-12-31 | 17.32% |
| 2020-09-30 | 20.59% |
| 2020-06-30 | -7.49% |
| 2020-03-31 | -26.43% |
| 2019-12-31 | -5.89% |
| 2019-09-30 | -16.71% |
| 2019-06-30 | -14.86% |
| 2019-03-31 | -27.43% |
| 2018-12-31 | -14.55% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | -7.56% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | -291.66% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
